{"gene":"ACKR2","run_date":"2026-06-09T22:02:38","timeline":{"discoveries":[{"year":1997,"finding":"Human ACKR2 (D6) is a promiscuous beta-chemokine receptor that binds the majority of CC chemokines but not alpha-chemokines, C, or CXXXC chemokines; unlike conventional chemokine receptors, it does not flux calcium upon ligand binding, indicating it lacks canonical signaling capacity.","method":"Radioligand binding assays in transfected CHO cells; calcium flux assays in HEK293 cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct binding assays and calcium flux experiments replicated independently for murine and human D6 in the same year across two papers","pmids":["9405404","9139699"],"is_preprint":false},{"year":1997,"finding":"Murine D6 binds multiple beta-chemokines with the order of affinity: murine MIP-1alpha > human/murine MIP-1beta > human RANTES ≈ JE > human MCP-3 > human MCP-1; alpha-chemokines did not compete; D6 does not function as an HIV-1 entry co-receptor on CD4+ cells.","method":"Competitive radioligand binding (125I-MIP-1alpha) in CHO transfectants; HIV infection assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — quantitative in vitro binding assays with multiple ligands, replicated across two independent 1997 papers","pmids":["9139699","9405404"],"is_preprint":false},{"year":2001,"finding":"ACKR2 (D6) is expressed by lymphatic endothelial cells of afferent lymphatics in human dermis, intestinal mucosa/submucosa, and lymph node sinuses, but not by blood vascular endothelium or peripheral blood cells, establishing its anatomical localization.","method":"Immunohistochemistry with monoclonal anti-D6 antibodies; in situ hybridization; co-staining with podoplanin lymphatic marker on serial sections","journal":"The American journal of pathology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal protein and mRNA detection with two orthogonal methods on multiple tissue types, replicated by subsequent studies","pmids":["11238036"],"is_preprint":false},{"year":2003,"finding":"ACKR2 (D6) engagement by inflammatory CC chemokines elicits no calcium response or chemotaxis but results in efficient agonist internalization and degradation; in lymphatic endothelium, D6 does not mediate transcytosis in either direction but solely internalizes and degrades chemokines.","method":"Calcium flux assays, chemotaxis assays, and chemokine internalization/degradation assays in D6 transfectants and primary lymphatic endothelial cells","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal functional assays in both transfected and primary cells; independently confirmed by subsequent studies","pmids":["12594248"],"is_preprint":false},{"year":2004,"finding":"D6 constitutively traffics to and from the cell surface via recycling endosomes in a ligand-independent manner; chemokines internalized by D6 dissociate from the receptor upon vesicle acidification and are degraded, while the receptor recycles to the surface without cell surface downregulation—unlike conventional receptors such as CCR5.","method":"Live-cell fluorescence microscopy, subcellular fractionation, chemokine internalization and degradation kinetics assays compared between D6 and CCR5 transfectants","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct localization by imaging plus functional chemokine trafficking assays with mechanistic comparator (CCR5), replicated conceptually across multiple subsequent studies","pmids":["15004236"],"is_preprint":false},{"year":2004,"finding":"ACKR2 (D6) constitutive internalization is mediated by the clathrin-coated pit pathway and requires constitutive association with beta-arrestin; an acidic region in the cytoplasmic tail (but not putative phosphorylation sites) is critical for beta-arrestin interaction and subsequent internalization; D6 does not activate any G-protein-mediated signaling pathway regardless of beta-arrestin coupling status.","method":"Clathrin pathway inhibitor studies; co-immunoprecipitation of D6 with beta-arrestin; C-terminal deletion/mutagenesis of D6; G-protein signaling assays in transfected cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal methods including mutagenesis and Co-IP; mechanistic dissection of distinct receptor domains","pmids":["15084596"],"is_preprint":false},{"year":2004,"finding":"Purified D6 protein retains full functional activity (displaceable 125I-MIP-1beta binding); D6 is N-glycosylated at the N-terminus (dispensable for ligand binding and high expression), sulphated, and constitutively phosphorylated in a ligand-independent manner; >80% of total cellular D6 is associated with intracellular vesicular structures.","method":"Protein purification, radioligand binding (125I-MIP-1beta), MIP-1alpha affinity column, N-terminal glycosylation mutants, metabolic labelling for sulphation and phosphorylation, subcellular fractionation","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstituted purified receptor functional assays combined with mutagenesis and metabolic labelling in a single study","pmids":["14723600"],"is_preprint":false},{"year":2004,"finding":"D6 efficiently binds and scavenges most inflammatory CCR1–CCR5 agonists but not homeostatic CCR6/CCR7 agonists; CCR4 agonists CCL17 and CCL22 are bound and scavenged by D6 but elicit no calcium flux or chemotaxis; CD26-processed truncated forms of CCL22 (lacking an intact N-terminus) are not recognized by D6.","method":"D6 transfectant binding assays, chemokine scavenging assays, calcium flux, chemotaxis assays, and testing of CD26-truncated CCL22 variants","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — systematic ligand panel with multiple functional readouts and N-terminal processing analysis in a single study","pmids":["15067078"],"is_preprint":false},{"year":2005,"finding":"D6-deficient mice develop exacerbated and prolonged cutaneous inflammatory responses following phorbol ester application, with excess beta-chemokines at the site; wild-type mice resolve the response, demonstrating that D6 is required for post-inflammatory clearance of CC chemokines from cutaneous sites.","method":"D6-knockout mouse model with phorbol ester-induced skin inflammation; ELISA chemokine quantification; histopathological analysis","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function in vivo with chemokine measurement and histopathology; independently replicated in multiple subsequent studies using D6-/- mice","pmids":["15750596"],"is_preprint":false},{"year":2005,"finding":"D6 can function as a coreceptor for primary dual-tropic HIV-1 and HIV-2 isolates on primary astrocytes; siRNA-mediated knockdown of D6 in primary astrocytes inhibited infection by D6-tropic isolates.","method":"HIV pseudovirus and primary isolate infection assays; siRNA knockdown of D6 in primary astrocytes; mRNA and immunoreactivity detection in macrophages and astrocytes","journal":"Journal of virology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — siRNA knockdown with defined functional readout in primary cells, single lab, single study","pmids":["16014924"],"is_preprint":false},{"year":2007,"finding":"D6 is expressed on the apical surface of syncytiotrophoblast cells and on invading extravillous trophoblasts in placenta; D6-deficient pregnant mice exposed to LPS or antiphospholipid autoantibodies show higher CC chemokine levels and increased leukocyte infiltrate in placenta, causing increased fetal loss that is prevented by blocking inflammatory chemokines.","method":"Immunohistochemistry with anti-D6 antibodies in placenta; D6-/- mouse model with LPS and antiphospholipid antibody challenges; chemokine ELISA; antibody-mediated chemokine blockade rescue experiment","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Moderate — loss-of-function with defined cellular mechanism and rescue experiment confirming chemokine-dependence, multiple orthogonal methods","pmids":["17283337"],"is_preprint":false},{"year":2008,"finding":"D6 scavenging activity depends on Rab4- and Rab11-dependent constitutive recycling; under resting conditions, D6 cycles via a rapid wortmannin-sensitive pathway and a slower BFA-sensitive pathway. Chemokine engagement induces dose-dependent, BFA-sensitive, Rab11-dependent redistribution of D6 to the cell membrane, increasing chemokine degradation rate without transcriptional upregulation.","method":"Wortmannin and brefeldin A (BFA) pharmacological inhibition; dominant-negative Rab4 and Rab11 overexpression; flow cytometry of surface D6; chemokine degradation assays in transfected cells","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — multiple pharmacological and dominant-negative genetic tools with quantitative functional readouts in a single study","pmids":["18480427"],"is_preprint":false},{"year":2008,"finding":"D6 expression in hematopoietic cells (B cells, dendritic cells, mast cells, megakaryocytes) is transcriptionally regulated by GATA1; D6 on human leukocytes mediates chemokine uptake as demonstrated by competition assays, whereas D6-null mouse cells fail to clear inflammatory chemokines.","method":"GATA1 knockdown/overexpression; promoter analysis; competition chemokine uptake assays in human leukocytes; comparison with D6-null mouse cells","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — GATA1 transcription factor regulation shown by functional promoter assays and leukocyte uptake experiments; single lab","pmids":["18714007","19039854"],"is_preprint":false},{"year":2008,"finding":"The conserved 58-amino acid C-terminal tail of D6 contains a serine cluster that controls constitutive phosphorylation, intracellular trafficking itinerary, and high receptor stability, and drives beta-arrestin to membranes near the cell surface; however, the C-terminus is dispensable for initial chemokine internalization. Without the C-terminus, initial CCL3 binding inhibits subsequent chemokine uptake, indicating the C-terminus prevents ligand-induced inhibition of receptor recycling and is required for progressive scavenging.","method":"C-terminal deletion and serine cluster mutants of D6-GFP; beta-arrestin-GFP recruitment assays; CCL3 scavenging assays in HEK293 cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis with defined functional readouts (trafficking, scavenging) and GFP-tagged protein reporters in a single mechanistic study","pmids":["18201974"],"is_preprint":false},{"year":2009,"finding":"D6-mediated chemokine degradation (but not binding) correlates with the receptor's adaptive surface upregulation; a proline residue at position 2 of D6-binding chemokines is dispensable for binding but is critical for D6 adaptive upregulation and efficient degradation, determining whether a bound chemokine is degraded or merely bound.","method":"D6 transfectant assays with panels of CC chemokines and their N-terminally truncated/processed isoforms; flow cytometry of surface D6; ELISA-based degradation assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — systematic structure-function analysis of chemokine N-termini with two orthogonal functional readouts; single lab","pmids":["19632987"],"is_preprint":false},{"year":2011,"finding":"D6 expressed on lymphatic endothelial cells prevents inflammatory CC chemokine binding to lymphatic surfaces, thereby avoiding inappropriate perilymphatic accumulation of inflammatory leukocytes; this prevents lymphatic congestion and maintains selective CCR7 ligand presentation, ensuring proper dendritic cell and fluid migration from inflamed tissues to lymph nodes.","method":"D6-/- mouse model; intravital microscopy; flow cytometry of LEC-bound chemokines; antigen-presenting cell migration assays; lymph node fluid drainage measurements","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function mouse model with multiple orthogonal readouts; independently confirmed by McKimmie et al. 2013","pmids":["21979941"],"is_preprint":false},{"year":2011,"finding":"D6 receptor activity (chemokine internalization) is a universal and unique feature of all known innate-like B-cell populations in mice; D6 on these cells internalizes chemokines but cannot induce Ca2+ fluxes or chemotaxis; additionally, D6 can suppress CXCR5 function in innate-like B cells.","method":"Flow cytometry-based chemokine uptake assay on primary B-cell subsets; Ca2+ flux assays; chemotaxis assays; analysis of D6-/- mice for B1 cell populations and anti-phosphorylcholine antibody levels","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — primary cell functional assays with loss-of-function confirmation; single lab, multiple orthogonal methods","pmids":["21450903"],"is_preprint":false},{"year":2013,"finding":"Engagement of ACKR2 (D6) by ligands activates a beta-arrestin1-dependent, G-protein-independent signaling pathway resulting in phosphorylation of cofilin through Rac1-PAK1-LIMK1 cascade; this pathway is required for ligand-induced D6 surface upregulation and chemokine-scavenging activity.","method":"Phospho-cofilin immunoblotting; dominant-negative Rac1 and PAK1 inhibitors; beta-arrestin1 siRNA knockdown; D6 surface expression and chemokine scavenging assays","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — novel signaling pathway established by multiple genetic and pharmacological perturbations with two orthogonal functional readouts; mechanistically distinct from prior models","pmids":["23633677"],"is_preprint":false},{"year":2013,"finding":"D6 on lymphatic endothelial cells (LECs) specifically regulates LEC discrimination between mature and immature dendritic cells; D6 overexpression reduces immature DC adhesion to LECs whereas D6 knockdown increases iDC adhesion and displacement of mature DCs. LEC D6 expression is upregulated by IL-6 and IFN-γ, and by Kaposi sarcoma-associated herpesvirus viral IL-6.","method":"D6 overexpression and knockdown in primary LEC cultures; DC adhesion assays; cytokine treatment; viral IL-6 overexpression in vitro and in vivo","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function experiments in primary cells with defined functional readout; single lab","pmids":["23479571"],"is_preprint":false},{"year":2013,"finding":"D6 expressed on apoptotic neutrophils plays a chemokine scavenging-independent role in promoting macrophage-mediated resolution of inflammation; D6-expressing apoptotic PMN suppress macrophage cytokine secretion (immune silencing) and modulate macrophage adhesive responses upon engulfment, effects abolished with D6-deficient PMN cells.","method":"In vivo peritonitis model with D6-/- mice; ex vivo macrophage-PMN co-culture efferocytosis and cytokine secretion assays; flow cytometry","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function in vivo and ex vivo with defined mechanistic output; single lab","pmids":["22651933"],"is_preprint":false},{"year":2014,"finding":"ACKR2 scavenges the CCL2 chemokine to reciprocally regulate lymphatic vessel density: ACKR2-deficient mice display increased lymphatic vessel density that is developmentally established, associated with enhanced macrophage proximity to developing lymphatic vessels; CCR2-deficient mice show the reciprocal phenotype of reduced vessel density.","method":"ACKR2-/- and CCR2-/- mouse models; immunofluorescence for lymphatic vessel density and macrophage localization; embryonic skin analysis; fluid drainage measurement","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal genetic loss-of-function with two knockout strains showing opposing phenotypes; multiple tissue analyses and developmental time points","pmids":["25271254"],"is_preprint":false},{"year":2014,"finding":"Primary human trophoblasts express ACKR2 at far higher levels than conventional inflammatory CC chemokine receptors and use ACKR2 to rapidly internalize and efficiently scavenge extracellular chemokines; in DBA/1j mice, ACKR2 deficiency in fetal cells causes placental structural defects, increased stillbirth, and reduced fetal weight.","method":"RT-PCR and flow cytometry of ACKR2 in primary human trophoblasts; chemokine internalization/scavenging assays; ACKR2-/- and fetal-specific ACKR2 knockout mouse models; placental histology","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — human primary cell functional assays plus fetal-specific mouse KO experiments with multiple orthogonal endpoints","pmids":["25297873"],"is_preprint":false},{"year":2016,"finding":"ACKR2 controls inflammatory T-cell chemotaxis and positioning within skin, preventing epidermal T-cell influx associated with lesion development; localized inflammation and IFN-γ upregulate ACKR2 in remote tissues, protecting them from spread of psoriasiform inflammation.","method":"Imiquimod-induced psoriasiform model in ACKR2-/- mice; in vitro T-cell migration assays; IFN-γ treatment of primary human cells; clinical skin biopsy analysis","journal":"The Journal of investigative dermatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function mouse model with defined cellular mechanism and in vitro confirmation; single lab","pmids":["27568525"],"is_preprint":false},{"year":2017,"finding":"miR-146b and miR-10b directly bind the ACKR2 3'-UTR and reduce ACKR2 transcript and protein expression in keratinocytes and lymphatic endothelial cells, respectively; tensile cell stress leads to rapid ACKR2 downregulation concurrent with miR-146b upregulation, providing a mechanism for trauma-induced reduction of ACKR2 (Koebner phenomenon).","method":"Luciferase 3'-UTR reporter assays; in silico miRNA target prediction; RT-PCR and Western blot in primary human cells; cell stretch/mechanical stress experiments","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — direct 3'-UTR reporter assay plus mechanical stress experiment in primary cells; single lab","pmids":["29279330"],"is_preprint":false},{"year":2018,"finding":"ACKR2 is expressed in hematopoietic precursors and downregulated during myeloid differentiation; genetic deletion of ACKR2 increases expression of inflammatory chemokine receptors on neutrophils and promotes their release from bone marrow with enhanced anti-metastatic activity.","method":"ACKR2-/- mouse models; flow cytometry of bone marrow and circulating cells; chemokine receptor expression profiling; in vivo metastasis models (4T1 mammary and B16F10 melanoma)","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function in vivo with defined cellular mechanism; single lab, multiple endpoints","pmids":["29445158"],"is_preprint":false},{"year":2018,"finding":"Ackr2 deficiency leads to increased CCR2 expression specifically on KLRG1+ NK cells, resulting in increased recruitment of these cells to CCL2-expressing tumors and enhanced tumor killing; Ackr2 thus limits CCR2 expression on NK cells and restricts their tumoricidal activity.","method":"Ackr2-/- mouse models; cell line and spontaneous metastasis models; flow cytometry for NK cell subset markers and CCR2 expression; in vivo tumor killing assays","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function mouse model with defined NK cell-CCR2 mechanism; single lab","pmids":["30158126"],"is_preprint":false},{"year":2019,"finding":"ACKR2 mediates CXCL14-stimulated epithelial-to-mesenchymal transition, migration, and invasion in breast cancer cells; ACKR2 loss-of-function abolishes CXCL14-induced responses, and downregulation of ACKR2 or CXCL14-induced NOS1 attenuates these pro-EMT effects, identifying an autocrine fibroblast CXCL14/ACKR2 pathway.","method":"siRNA knockdown of ACKR2 in breast cancer cells; in vitro EMT, migration, invasion assays; in vivo xenograft and tail-vein metastasis models; NOS1 inhibition","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with defined signaling mechanism and in vivo confirmation; single lab","pmids":["30850359"],"is_preprint":false},{"year":2021,"finding":"CXCL10 (a CXC chemokine) is an agonist ligand for ACKR2, able to recruit beta-arrestin and be internalized and degraded by ACKR2, expanding the receptor's ligand range beyond CC chemokines; CD26/DPP4 N-terminal processing of CXCL10 drastically reduces its activity toward ACKR2, suggesting a different receptor binding pocket occupancy than CC chemokines.","method":"Beta-arrestin recruitment assays using NanoBiT and NanoBRET technologies; chemokine internalization and extracellular availability assays; DPP4-processed CXCL10 functional testing","journal":"Cancers","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — highly sensitive functional assays with two orthogonal technologies; single lab; expands established paradigm","pmids":["33801414"],"is_preprint":false},{"year":2021,"finding":"Sirtuin 2 (SIRT2) promotes p65 deacetylation to suppress miR-146a expression, which in turn targets ACKR2; downregulation of miR-146a thus upregulates ACKR2 in trophoblasts, enhancing their proliferation, migration, and invasion; this SIRT2/p65/miR-146a/ACKR2 axis is disrupted in preeclampsia.","method":"ChIP assay; luciferase reporter assay confirming miR-146a targeting of ACKR2 3'-UTR; SIRT2 overexpression; miR-146a overexpression; HTR-8/SVneo trophoblast cell functional assays","journal":"Reproductive sciences","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — ChIP and luciferase assays with mechanistic chain confirmed by gain/loss-of-function; single lab","pmids":["33409877"],"is_preprint":false},{"year":2023,"finding":"ACKR2 mediates CXCL14-induced lung cancer cell metastasis through activation of PLCβ3, PKCα, and c-Src signaling, subsequently upregulating NF-κB transcription activity leading to EMT and increased cell migration; ACKR2 knockdown abolishes CXCL14-induced cancer cell motility.","method":"ACKR2 knockdown studies; Western blot for PLCβ3/PKCα/c-Src/NF-κB pathway activation; luciferase NF-κB reporter assay; migration and wound healing assays; orthotopic mouse metastasis model","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with defined signaling cascade and in vivo confirmation; single lab","pmids":["37056937"],"is_preprint":false},{"year":2024,"finding":"ACKR2+ chemoradiotherapy-resistant tumor cells drive CD8+ T cell senescence by producing TGF-β in response to CC chemokines produced by activated myeloid and T cells; ACKR2 expression in tumor cells is upregulated by chemoradiotherapy and by CC chemokine ligation, creating a feed-forward loop that compromises antitumor immunity.","method":"Single-cell RNA sequencing of human cervical cancer tissues before/after CCRT; mechanistic validation of ACKR2-TGF-β-CD8+ T cell senescence axis in functional assays","journal":"Cell reports. Medicine","confidence":"Low","confidence_rationale":"Tier 3 / Weak — mechanistic claim derived primarily from single-cell transcriptomics with limited direct experimental validation described in abstract; single study","pmids":["38723624"],"is_preprint":false}],"current_model":"ACKR2 (D6) is a heptahelical atypical chemokine receptor that constitutively cycles through Rab4/Rab11-dependent recycling endosomes to the plasma membrane, where it binds and internalizes most inflammatory CC chemokines (and CXCL10) via the clathrin pathway in a beta-arrestin-dependent manner; internalized chemokines dissociate from the receptor upon vesicle acidification and are degraded while the receptor recycles, maintaining surface expression; ligand engagement activates a beta-arrestin1/Rac1/PAK1/LIMK1/cofilin pathway that drives adaptive surface upregulation to increase scavenging capacity; the C-terminal serine cluster controls receptor stability, constitutive phosphorylation, and trafficking to prevent ligand-induced inhibition of recycling; expressed prominently on lymphatic endothelial cells, trophoblasts, and hematopoietic cells (regulated by GATA1 and miR-146b/miR-10b), ACKR2 scavenges inflammatory CC chemokines to suppress inflammation, regulate lymphatic vessel density and function, modulate neutrophil and NK cell trafficking, and protect against fetal loss and pathological inflammation in multiple tissues."},"narrative":{"mechanistic_narrative":"ACKR2 (D6) is an atypical, non-signaling chemokine scavenging receptor that suppresses inflammation by binding, internalizing, and degrading the majority of inflammatory CC chemokines (and CXCL10) without coupling to the canonical G-protein calcium/chemotaxis output of conventional chemokine receptors [PMID:9405404, PMID:9139699, PMID:12594248, PMID:33801414]. Mechanistically, the receptor constitutively cycles between recycling endosomes and the plasma membrane in a ligand-independent, Rab4/Rab11-dependent manner; internalized chemokines dissociate upon endosomal acidification and are degraded while the receptor recycles back to the surface without downregulation, enabling sustained scavenging [PMID:15004236, PMID:18480427]. Internalization proceeds through the clathrin pathway and requires constitutive association with beta-arrestin via an acidic cytoplasmic-tail region, while the conserved C-terminal serine cluster controls constitutive phosphorylation, receptor stability, trafficking itinerary, and prevents ligand-induced inhibition of recycling to permit progressive scavenging [PMID:15084596, PMID:18201974]. Ligand engagement triggers a beta-arrestin1-dependent, G-protein-independent Rac1–PAK1–LIMK1–cofilin cascade that drives adaptive surface upregulation and increases scavenging capacity, with chemokine degradation (distinct from mere binding) determined by an N-terminal proline at ligand position 2 [PMID:19632987, PMID:23633677]. Expressed prominently on lymphatic endothelial cells, trophoblasts, and hematopoietic cells, ACKR2 limits perilymphatic accumulation of inflammatory leukocytes and preserves CCR7-dependent dendritic cell migration, reciprocally regulates lymphatic vessel density through CCL2 clearance, restricts neutrophil and NK-cell trafficking, and protects against inflammation-driven fetal loss [PMID:17283337, PMID:21979941, PMID:25271254, PMID:25297873, PMID:29445158, PMID:30158126]. In vivo loss of ACKR2 produces exacerbated, poorly resolving inflammatory responses with excess local CC chemokines [PMID:15750596]. In tumor contexts, ACKR2 also transduces CXCL14-driven EMT and metastatic signaling [PMID:30850359, PMID:37056937].","teleology":[{"year":1997,"claim":"Established that ACKR2 is a promiscuous CC chemokine binder that, unlike conventional chemokine receptors, fails to flux calcium, defining it as a non-signaling receptor and raising the question of its function.","evidence":"Radioligand binding and calcium flux assays in transfected CHO and HEK293 cells for human and murine D6","pmids":["9405404","9139699"],"confidence":"High","gaps":["Did not establish the cellular fate of bound chemokines","No in vivo function defined"]},{"year":2001,"claim":"Localized ACKR2 to lymphatic endothelium of afferent lymphatics and lymph node sinuses, anchoring its function to a specific anatomical compartment rather than blood vasculature.","evidence":"Immunohistochemistry, in situ hybridization, and podoplanin co-staining across human tissues","pmids":["11238036"],"confidence":"High","gaps":["Did not test functional consequence of lymphatic expression","Hematopoietic expression not yet defined"]},{"year":2003,"claim":"Resolved the receptor's function by showing that ligand engagement leads to efficient internalization and degradation rather than transcytosis or chemotaxis, defining ACKR2 as a chemokine scavenger.","evidence":"Internalization/degradation assays in transfectants and primary lymphatic endothelial cells","pmids":["12594248"],"confidence":"High","gaps":["Trafficking machinery not yet identified","Did not determine how the receptor avoids downregulation"]},{"year":2004,"claim":"Defined the trafficking logic of scavenging: constitutive ligand-independent recycling with endosomal acidification driving chemokine release and degradation while the receptor returns to the surface.","evidence":"Live-cell imaging, subcellular fractionation, and degradation kinetics comparing D6 to CCR5","pmids":["15004236"],"confidence":"High","gaps":["Specific Rab GTPases not yet identified","Endocytic adaptors not yet defined"]},{"year":2004,"claim":"Identified the internalization machinery and biochemical features, showing clathrin- and beta-arrestin-dependent uptake via an acidic tail region and confirming the absence of G-protein signaling.","evidence":"Clathrin inhibitors, beta-arrestin Co-IP, C-terminal mutagenesis, G-protein assays, and purified-receptor binding plus metabolic labelling","pmids":["15084596","14723600"],"confidence":"High","gaps":["Role of C-terminal phosphorylation in trafficking unresolved","Did not address adaptive surface regulation"]},{"year":2004,"claim":"Defined the ligand spectrum, establishing that ACKR2 scavenges inflammatory but not homeostatic chemokines and that intact chemokine N-termini are required for recognition.","evidence":"Systematic chemokine binding/scavenging panel including CD26-truncated CCL22 in transfectants","pmids":["15067078"],"confidence":"High","gaps":["Did not distinguish binding from degradation determinants","Did not extend to CXC chemokines"]},{"year":2005,"claim":"Provided the first in vivo loss-of-function evidence that ACKR2 is required to resolve cutaneous inflammation by clearing CC chemokines.","evidence":"Phorbol ester skin inflammation in D6-knockout mice with chemokine ELISA and histopathology","pmids":["15750596"],"confidence":"High","gaps":["Cell-type-specific contributions not dissected","Did not address other tissues"]},{"year":2005,"claim":"Raised an alternative pathogen-related role by implicating D6 as an HIV coreceptor on primary astrocytes.","evidence":"HIV infection assays with siRNA knockdown in primary astrocytes","pmids":["16014924"],"confidence":"Medium","gaps":["Single lab, single study","Conflicts with earlier finding that D6 is not an HIV coreceptor on CD4+ cells","Physiological relevance unclear"]},{"year":2007,"claim":"Extended scavenging function to the placenta, showing ACKR2 protects against inflammation-driven fetal loss in a chemokine-dependent manner.","evidence":"Placental immunohistochemistry plus D6-/- LPS/antiphospholipid challenge with chemokine-blockade rescue","pmids":["17283337"],"confidence":"High","gaps":["Maternal versus fetal source of ACKR2 not resolved here","Mechanism of trophoblast scavenging not detailed"]},{"year":2008,"claim":"Identified the trafficking machinery and the adaptive scavenging mechanism: Rab4/Rab11-dependent recycling and ligand-induced membrane redistribution that boosts degradation without transcription.","evidence":"Wortmannin/BFA inhibition, dominant-negative Rab4/Rab11, flow cytometry, and degradation assays","pmids":["18480427"],"confidence":"High","gaps":["Signaling driving redistribution not yet identified","Link to C-terminal regulation unresolved"]},{"year":2008,"claim":"Defined transcriptional control by GATA1 and confirmed functional scavenging on human leukocytes, broadening expression beyond endothelium to hematopoietic cells.","evidence":"GATA1 perturbation, promoter analysis, and leukocyte uptake assays versus D6-null cells","pmids":["18714007","19039854"],"confidence":"Medium","gaps":["Single lab","Direct GATA1 binding to endogenous locus not fully mapped"]},{"year":2008,"claim":"Dissected the C-terminal serine cluster's role in phosphorylation, stability, trafficking, and prevention of ligand-induced inhibition of recycling required for progressive scavenging.","evidence":"C-terminal/serine-cluster mutants of D6-GFP with beta-arrestin recruitment and CCL3 scavenging assays","pmids":["18201974"],"confidence":"High","gaps":["Identity of the kinase phosphorylating the serine cluster unknown","Did not connect to the downstream signaling cascade"]},{"year":2009,"claim":"Separated binding from degradation, identifying a chemokine position-2 proline as the determinant of adaptive upregulation and efficient degradation.","evidence":"Chemokine N-terminal isoform panels with surface D6 flow cytometry and degradation ELISA","pmids":["19632987"],"confidence":"Medium","gaps":["Single lab","Structural basis of proline recognition not determined"]},{"year":2011,"claim":"Established the lymphatic physiological role: ACKR2 prevents perilymphatic inflammatory chemokine accumulation to preserve CCR7-dependent dendritic cell and fluid migration.","evidence":"D6-/- intravital microscopy, LEC chemokine flow cytometry, and APC migration/drainage assays","pmids":["21979941"],"confidence":"High","gaps":["Did not address lymphatic developmental patterning","Cell-intrinsic versus tissue effects not fully separated"]},{"year":2011,"claim":"Showed ACKR2 scavenging is a universal feature of innate-like B cells and can suppress CXCR5 function, linking it to B-cell positioning.","evidence":"Chemokine uptake, Ca2+ flux, chemotaxis assays on primary B-cell subsets and D6-/- analysis","pmids":["21450903"],"confidence":"Medium","gaps":["Single lab","Mechanism of CXCR5 suppression unresolved"]},{"year":2013,"claim":"Identified the signaling cascade behind adaptive scavenging: a beta-arrestin1/Rac1/PAK1/LIMK1/cofilin pathway driving surface upregulation, reconciling a non-G-protein receptor with active signaling output.","evidence":"Phospho-cofilin immunoblotting, dominant-negative Rac1/PAK1, beta-arrestin1 siRNA, and scavenging assays","pmids":["23633677"],"confidence":"High","gaps":["How ligand binding initiates the cascade not fully defined","In vivo relevance of the cascade untested"]},{"year":2013,"claim":"Connected lymphatic ACKR2 to immune surveillance by showing it controls LEC discrimination between mature and immature dendritic cells, with cytokine and viral IL-6 regulation.","evidence":"LEC overexpression/knockdown DC adhesion assays with IL-6/IFN-gamma and viral IL-6 treatment","pmids":["23479571"],"confidence":"Medium","gaps":["Single lab","Molecular basis of DC discrimination unresolved"]},{"year":2014,"claim":"Revealed a developmental role linking CCL2 scavenging to reciprocal control of lymphatic vessel density via macrophage proximity.","evidence":"Reciprocal ACKR2-/- and CCR2-/- mouse phenotyping with embryonic skin imaging and drainage measurement","pmids":["25271254"],"confidence":"High","gaps":["Macrophage signal driving lymphangiogenesis not fully defined","Direct CCL2 gradients not measured in vivo"]},{"year":2014,"claim":"Demonstrated that trophoblast-intrinsic ACKR2 mediates chemokine scavenging required for normal placental structure and fetal viability.","evidence":"Primary human trophoblast scavenging assays and fetal-specific ACKR2 knockout mouse models","pmids":["25297873"],"confidence":"High","gaps":["Specific pathogenic chemokines in placenta not fully resolved","Mechanism of structural defect unclear"]},{"year":2016,"claim":"Showed ACKR2 controls inflammatory T-cell positioning in skin and protects remote tissues from psoriasiform inflammation spread, induced by IFN-gamma.","evidence":"Imiquimod psoriasiform model in ACKR2-/- mice with T-cell migration assays and clinical biopsies","pmids":["27568525"],"confidence":"Medium","gaps":["Single lab","Remote-tissue protection mechanism partial"]},{"year":2017,"claim":"Identified post-transcriptional control of ACKR2 by miR-146b and miR-10b, including stress-induced downregulation, providing a mechanism for trauma-triggered loss of scavenging.","evidence":"3'-UTR luciferase reporters and cell-stretch experiments in primary keratinocytes and LECs","pmids":["29279330"],"confidence":"Medium","gaps":["Single lab","In vivo relevance of miRNA regulation untested"]},{"year":2018,"claim":"Linked ACKR2 to myeloid development and neutrophil release, showing its deletion enhances anti-metastatic neutrophil activity by raising inflammatory chemokine receptor expression.","evidence":"ACKR2-/- bone marrow profiling and 4T1/B16F10 metastasis models","pmids":["29445158"],"confidence":"Medium","gaps":["Single lab","Cell-intrinsic versus niche effects not fully separated"]},{"year":2018,"claim":"Showed ACKR2 limits CCR2 expression on KLRG1+ NK cells, restricting their CCL2-driven recruitment and tumoricidal activity.","evidence":"Ackr2-/- metastasis models with NK subset flow cytometry and in vivo killing assays","pmids":["30158126"],"confidence":"Medium","gaps":["Single lab","Mechanism of CCR2 limitation on NK cells unresolved"]},{"year":2019,"claim":"Reframed ACKR2 in cancer as a signaling receptor mediating CXCL14-induced EMT, migration, and invasion via NOS1 in breast cancer cells.","evidence":"ACKR2 siRNA knockdown with EMT/migration/invasion assays and xenograft/metastasis models","pmids":["30850359"],"confidence":"Medium","gaps":["Single lab","Reconciliation with non-signaling scavenger model not addressed"]},{"year":2021,"claim":"Expanded the ligand range by establishing CXCL10 as a CC-independent agonist that recruits beta-arrestin and is degraded, with distinct binding-pocket determinants.","evidence":"NanoBiT/NanoBRET beta-arrestin recruitment and internalization assays plus DPP4-processed CXCL10 testing","pmids":["33801414"],"confidence":"Medium","gaps":["Single lab","Structural basis of CXC versus CC recognition not determined"]},{"year":2021,"claim":"Defined an upstream regulatory axis (SIRT2/p65/miR-146a) controlling trophoblast ACKR2 expression and linked its disruption to preeclampsia.","evidence":"ChIP, miR-146a 3'-UTR luciferase reporters, and SIRT2/miR-146a perturbation in HTR-8/SVneo trophoblasts","pmids":["33409877"],"confidence":"Medium","gaps":["Single lab","In vivo validation of the axis limited"]},{"year":2023,"claim":"Extended the CXCL14/ACKR2 signaling axis to lung cancer, mapping a PLCβ3/PKCα/c-Src/NF-κB cascade driving EMT and metastasis.","evidence":"ACKR2 knockdown with pathway immunoblotting, NF-kB luciferase, migration assays, and orthotopic metastasis model","pmids":["37056937"],"confidence":"Medium","gaps":["Single lab","Receptor coupling mechanism to PLCβ3 not defined"]},{"year":2024,"claim":"Proposed that ACKR2+ chemoradiotherapy-resistant tumor cells drive CD8+ T-cell senescence through CC-chemokine-induced TGF-beta in a feed-forward loop.","evidence":"Single-cell RNA sequencing of human cervical cancer with mechanistic validation of the ACKR2-TGF-beta-senescence axis","pmids":["38723624"],"confidence":"Low","gaps":["Mechanistic claim derived primarily from transcriptomics with limited direct validation","Single study","Causality of ACKR2 in TGF-beta production not firmly established"]},{"year":null,"claim":"How the canonical non-signaling scavenging role of ACKR2 mechanistically reconciles with its reported active CXCL14-driven pro-tumor signaling remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model linking ligand-binding pocket to either scavenging or signaling output","No unified framework explaining context-dependent signaling versus scavenging"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,3,7]},{"term_id":"GO:0140313","term_label":"molecular sequestering activity","supporting_discovery_ids":[3,4,11]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[5,13,17]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[4,11]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[4,6,11]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[6]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[8,15,19]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[4,5,11]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[17]},{"term_id":"R-HSA-1500931","term_label":"Cell-Cell communication","supporting_discovery_ids":[0,3,7]}],"complexes":[],"partners":["ARRB1","RAC1","PAK1","LIMK1","CFL1","RAB11A","RAB4A"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O00590","full_name":"Atypical chemokine receptor 2","aliases":["C-C chemokine receptor D6","Chemokine receptor CCR-10","Chemokine receptor CCR-9","Chemokine-binding protein 2","Chemokine-binding protein D6"],"length_aa":384,"mass_kda":43.4,"function":"Atypical chemokine receptor that controls chemokine levels and localization via high-affinity chemokine binding that is uncoupled from classic ligand-driven signal transduction cascades, resulting instead in chemokine sequestration, degradation, or transcytosis (PubMed:18201974, PubMed:20373092, PubMed:23479571). Also known as interceptor (internalizing receptor) or chemokine-scavenging receptor or chemokine decoy receptor (PubMed:18201974, PubMed:20373092, PubMed:23479571). Acts as a receptor for chemokines including CCL2, CCL3, CCL3L1, CCL4, CCL5, CCL7, CCL8, CCL11, CCL13, CCL17, CCL22, CCL23, CCL24, SCYA2/MCP-1, SCY3/MIP-1-alpha, SCYA5/RANTES and SCYA7/MCP-3 (PubMed:18201974, PubMed:20373092, PubMed:23479571). Upon active ligand stimulation, activates a beta-arrestin 1 (ARRB1)-dependent, G protein-independent signaling pathway that results in the phosphorylation of the actin-binding protein cofilin (CFL1) through a RAC1-PAK1-LIMK1 signaling pathway (PubMed:23633677). Activation of this pathway results in up-regulation of ACKR2 from endosomal compartment to cell membrane, increasing its efficiency in chemokine uptake and degradation (PubMed:23633677). By scavenging chemokines in tissues, on the surfaces of lymphatic vessels, and in placenta, plays an essential role in the resolution (termination) of the inflammatory response and in the regulation of adaptive immune responses (PubMed:23479571). Plays a major role in the immune silencing of macrophages during the resolution of inflammation (By similarity). Acts as a regulator of inflammatory leukocyte interactions with lymphatic endothelial cells (LECs) and is required for immature/mature dendritic cells discrimination by LECs (PubMed:23479571)","subcellular_location":"Early endosome; Recycling endosome; Cell membrane","url":"https://www.uniprot.org/uniprotkb/O00590/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ACKR2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ACKR2","total_profiled":1310},"omim":[{"mim_id":"602648","title":"ATYPICAL CHEMOKINE RECEPTOR 2; ACKR2","url":"https://www.omim.org/entry/602648"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Vesicles","reliability":"Supported"},{"location":"Cytosol","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"liver","ntpm":8.8},{"tissue":"placenta","ntpm":15.0}],"url":"https://www.proteinatlas.org/search/ACKR2"},"hgnc":{"alias_symbol":["CCR10","D6","CCR9"],"prev_symbol":["CMKBR9","CCBP2"]},"alphafold":{"accession":"O00590","domains":[{"cath_id":"1.20.1070.10","chopping":"58-331","consensus_level":"high","plddt":89.2259,"start":58,"end":331}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O00590","model_url":"https://alphafold.ebi.ac.uk/files/AF-O00590-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O00590-F1-predicted_aligned_error_v6.png","plddt_mean":80.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ACKR2","jax_strain_url":"https://www.jax.org/strain/search?query=ACKR2"},"sequence":{"accession":"O00590","fasta_url":"https://rest.uniprot.org/uniprotkb/O00590.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O00590/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O00590"}},"corpus_meta":[{"pmid":"20024327","id":"PMC_20024327","title":"Application of d6 transition metal complexes in fluorescence cell imaging.","date":"2009","source":"Chemical communications (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/20024327","citation_count":425,"is_preprint":false},{"pmid":"15750596","id":"PMC_15750596","title":"The chemokine receptor D6 limits the inflammatory response in vivo.","date":"2005","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15750596","citation_count":252,"is_preprint":false},{"pmid":"11238036","id":"PMC_11238036","title":"The beta-chemokine receptor D6 is expressed by lymphatic endothelium and a subset of vascular tumors.","date":"2001","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11238036","citation_count":236,"is_preprint":false},{"pmid":"24948515","id":"PMC_24948515","title":"Auxin efflux by PIN-FORMED proteins is activated by two different protein kinases, D6 PROTEIN KINASE and PINOID.","date":"2014","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/24948515","citation_count":208,"is_preprint":false},{"pmid":"9405404","id":"PMC_9405404","title":"Cloning and characterization of a novel promiscuous human beta-chemokine receptor D6.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9405404","citation_count":178,"is_preprint":false},{"pmid":"16849554","id":"PMC_16849554","title":"Systemic induction of the angiogenesis switch by the tetraspanin D6.1A/CO-029.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16849554","citation_count":178,"is_preprint":false},{"pmid":"12594248","id":"PMC_12594248","title":"Cutting edge: scavenging of inflammatory CC chemokines by the promiscuous putatively silent chemokine receptor D6.","date":"2003","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12594248","citation_count":165,"is_preprint":false},{"pmid":"15004236","id":"PMC_15004236","title":"The chemokine receptor D6 constitutively traffics to and from the cell surface to internalize and degrade chemokines.","date":"2004","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/15004236","citation_count":164,"is_preprint":false},{"pmid":"17283337","id":"PMC_17283337","title":"Protection against inflammation- and autoantibody-caused fetal loss by the chemokine decoy receptor D6.","date":"2007","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/17283337","citation_count":153,"is_preprint":false},{"pmid":"15084596","id":"PMC_15084596","title":"beta-Arrestin-dependent constitutive internalization of the human chemokine decoy receptor D6.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15084596","citation_count":136,"is_preprint":false},{"pmid":"19846409","id":"PMC_19846409","title":"The lymphatic system controls intestinal inflammation and inflammation-associated Colon Cancer through the chemokine decoy receptor D6.","date":"2009","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/19846409","citation_count":131,"is_preprint":false},{"pmid":"17607362","id":"PMC_17607362","title":"The atypical chemokine receptor D6 suppresses the development of chemically induced skin tumors.","date":"2007","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/17607362","citation_count":129,"is_preprint":false},{"pmid":"15789340","id":"PMC_15789340","title":"Increased inflammation in mice deficient for the chemokine decoy receptor D6.","date":"2005","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15789340","citation_count":119,"is_preprint":false},{"pmid":"9139699","id":"PMC_9139699","title":"Cloning and characterization of a novel murine beta chemokine receptor, D6. Comparison to three other related macrophage inflammatory protein-1alpha receptors, CCR-1, CCR-3, and CCR-5.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9139699","citation_count":117,"is_preprint":false},{"pmid":"15067078","id":"PMC_15067078","title":"Differential recognition and scavenging of native and truncated macrophage-derived chemokine (macrophage-derived chemokine/CC chemokine ligand 22) by the D6 decoy receptor.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15067078","citation_count":116,"is_preprint":false},{"pmid":"19130487","id":"PMC_19130487","title":"D6 and the atypical chemokine receptor family: novel regulators of immune and inflammatory processes.","date":"2009","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19130487","citation_count":115,"is_preprint":false},{"pmid":"24930721","id":"PMC_24930721","title":"D6 PROTEIN KINASE activates auxin transport-dependent growth and PIN-FORMED phosphorylation at the plasma membrane.","date":"2014","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/24930721","citation_count":99,"is_preprint":false},{"pmid":"30850359","id":"PMC_30850359","title":"A Novel ACKR2-Dependent Role of Fibroblast-Derived CXCL14 in Epithelial-to-Mesenchymal Transition and Metastasis of Breast Cancer.","date":"2019","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/30850359","citation_count":99,"is_preprint":false},{"pmid":"15996892","id":"PMC_15996892","title":"Silent chemoattractant receptors: D6 as a decoy and scavenger receptor for inflammatory CC chemokines.","date":"2005","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/15996892","citation_count":93,"is_preprint":false},{"pmid":"18695004","id":"PMC_18695004","title":"Role of the chemokine decoy receptor D6 in balancing inflammation, immune activation, and antimicrobial resistance in Mycobacterium tuberculosis infection.","date":"2008","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18695004","citation_count":88,"is_preprint":false},{"pmid":"15001178","id":"PMC_15001178","title":"Chemokines on the move: control by the chemokine \"interceptors\" Duffy blood group antigen and D6.","date":"2003","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15001178","citation_count":81,"is_preprint":false},{"pmid":"29445158","id":"PMC_29445158","title":"ACKR2 in hematopoietic precursors as a checkpoint of neutrophil release and anti-metastatic activity.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29445158","citation_count":78,"is_preprint":false},{"pmid":"18480427","id":"PMC_18480427","title":"Regulation of D6 chemokine scavenging activity by ligand- and Rab11-dependent surface up-regulation.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18480427","citation_count":76,"is_preprint":false},{"pmid":"27836964","id":"PMC_27836964","title":"Phospholipid composition and a polybasic motif determine D6 PROTEIN KINASE polar association with the plasma membrane and tropic responses.","date":"2016","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/27836964","citation_count":76,"is_preprint":false},{"pmid":"18714007","id":"PMC_18714007","title":"Hemopoietic cell expression of the chemokine decoy receptor D6 is dynamic and regulated by GATA1.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18714007","citation_count":75,"is_preprint":false},{"pmid":"17095748","id":"PMC_17095748","title":"The chemokine receptor D6 has opposing effects on allergic inflammation and airway reactivity.","date":"2006","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17095748","citation_count":75,"is_preprint":false},{"pmid":"22796582","id":"PMC_22796582","title":"The chemokine decoy receptor D6 prevents excessive inflammation and adverse ventricular remodeling after myocardial infarction.","date":"2012","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/22796582","citation_count":74,"is_preprint":false},{"pmid":"21979941","id":"PMC_21979941","title":"D6 facilitates cellular migration and fluid flow to lymph nodes by suppressing lymphatic congestion.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21979941","citation_count":72,"is_preprint":false},{"pmid":"21450903","id":"PMC_21450903","title":"Universal expression and dual function of the atypical chemokine receptor D6 on innate-like B cells in mice.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21450903","citation_count":70,"is_preprint":false},{"pmid":"23479571","id":"PMC_23479571","title":"An analysis of the function and expression of D6 on lymphatic endothelial cells.","date":"2013","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/23479571","citation_count":69,"is_preprint":false},{"pmid":"18708360","id":"PMC_18708360","title":"Chemokine decoy receptor d6 plays a negative role in human breast cancer.","date":"2008","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/18708360","citation_count":69,"is_preprint":false},{"pmid":"16785491","id":"PMC_16785491","title":"Cutting edge: the silent chemokine receptor D6 is required for generating T cell responses that mediate experimental autoimmune encephalomyelitis.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16785491","citation_count":69,"is_preprint":false},{"pmid":"25271254","id":"PMC_25271254","title":"The chemokine receptors ACKR2 and CCR2 reciprocally regulate lymphatic vessel density.","date":"2014","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/25271254","citation_count":63,"is_preprint":false},{"pmid":"23633677","id":"PMC_23633677","title":"β-arrestin-dependent activation of the cofilin pathway is required for the scavenging activity of the atypical chemokine receptor D6.","date":"2013","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/23633677","citation_count":63,"is_preprint":false},{"pmid":"16014924","id":"PMC_16014924","title":"The promiscuous CC chemokine receptor D6 is a functional coreceptor for primary isolates of human immunodeficiency virus type 1 (HIV-1) and HIV-2 on astrocytes.","date":"2005","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/16014924","citation_count":63,"is_preprint":false},{"pmid":"14723600","id":"PMC_14723600","title":"Purification and biochemical characterization of the D6 chemokine receptor.","date":"2004","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/14723600","citation_count":61,"is_preprint":false},{"pmid":"18201974","id":"PMC_18201974","title":"Multiple roles for the C-terminal tail of the chemokine scavenger D6.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18201974","citation_count":58,"is_preprint":false},{"pmid":"13130099","id":"PMC_13130099","title":"The association of the tetraspanin D6.1A with the alpha6beta4 integrin supports cell motility and liver metastasis formation.","date":"2003","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/13130099","citation_count":58,"is_preprint":false},{"pmid":"23413964","id":"PMC_23413964","title":"Solution-state 2D NMR spectroscopy of plant cell walls enabled by a dimethylsulfoxide-d6/1-ethyl-3-methylimidazolium acetate solvent.","date":"2013","source":"Analytical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23413964","citation_count":57,"is_preprint":false},{"pmid":"23125030","id":"PMC_23125030","title":"Regulation of the immune and inflammatory responses by the 'atypical' chemokine receptor D6.","date":"2013","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23125030","citation_count":52,"is_preprint":false},{"pmid":"16814608","id":"PMC_16814608","title":"Chemokine scavenging by D6: a movable feast?","date":"2006","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16814608","citation_count":52,"is_preprint":false},{"pmid":"27098058","id":"PMC_27098058","title":"Comparison of differences in development potentials between frozen-thawed D5 and D6 blastocysts and their relationship with pregnancy outcomes.","date":"2016","source":"Journal of assisted reproduction and genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27098058","citation_count":52,"is_preprint":false},{"pmid":"12088753","id":"PMC_12088753","title":"Forebrain-specific promoter/enhancer D6 derived from the mouse Dach1 gene controls expression in neural stem cells.","date":"2002","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/12088753","citation_count":50,"is_preprint":false},{"pmid":"20147628","id":"PMC_20147628","title":"Chemokine scavenger D6 is expressed by trophoblasts and aids the survival of mouse embryos transferred into allogeneic recipients.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/20147628","citation_count":49,"is_preprint":false},{"pmid":"19632987","id":"PMC_19632987","title":"Recognition versus adaptive up-regulation and degradation of CC chemokines by the chemokine decoy receptor D6 are determined by their N-terminal sequence.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19632987","citation_count":47,"is_preprint":false},{"pmid":"19342683","id":"PMC_19342683","title":"The atypical chemokine receptor D6 contributes to the development of experimental colitis.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19342683","citation_count":46,"is_preprint":false},{"pmid":"15725074","id":"PMC_15725074","title":"The tetraspanin D6.1A and its molecular partners on rat carcinoma cells.","date":"2005","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/15725074","citation_count":45,"is_preprint":false},{"pmid":"33801414","id":"PMC_33801414","title":"CXCL10 Is an Agonist of the CC Family Chemokine Scavenger Receptor ACKR2/D6.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33801414","citation_count":42,"is_preprint":false},{"pmid":"19039854","id":"PMC_19039854","title":"Hemopoietic cell expression of the chemokine decoy receptor D6 is dynamic and regulated by GATA1.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19039854","citation_count":40,"is_preprint":false},{"pmid":"21151196","id":"PMC_21151196","title":"DARC and D6: silent partners in chemokine regulation?","date":"2010","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/21151196","citation_count":39,"is_preprint":false},{"pmid":"22867710","id":"PMC_22867710","title":"Elevated expression of the chemokine-scavenging receptor D6 is associated with impaired lesion development in psoriasis.","date":"2012","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/22867710","citation_count":39,"is_preprint":false},{"pmid":"22797410","id":"PMC_22797410","title":"Expression of the atypical chemokine receptor D6 in human alveolar macrophages in COPD.","date":"2013","source":"Chest","url":"https://pubmed.ncbi.nlm.nih.gov/22797410","citation_count":39,"is_preprint":false},{"pmid":"23381581","id":"PMC_23381581","title":"Specific humoral immune response to the Thomsen-Friedenreich tumor antigen (CD176) in mice after vaccination with the commensal bacterium Bacteroides ovatus D-6.","date":"2013","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/23381581","citation_count":39,"is_preprint":false},{"pmid":"38723624","id":"PMC_38723624","title":"Chemoradiotherapy-induced ACKR2+ tumor cells drive CD8+ T cell senescence and cervical cancer recurrence.","date":"2024","source":"Cell reports. Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38723624","citation_count":36,"is_preprint":false},{"pmid":"24844911","id":"PMC_24844911","title":"ERK-dependent downregulation of the atypical chemokine receptor D6 drives tumor aggressiveness in Kaposi sarcoma.","date":"2014","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/24844911","citation_count":35,"is_preprint":false},{"pmid":"29469612","id":"PMC_29469612","title":"The atypical chemokine receptor ACKR2 drives pulmonary fibrosis by tuning influx of CCR2+ and CCR5+ IFNγ-producing γδT cells in mice.","date":"2018","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/29469612","citation_count":34,"is_preprint":false},{"pmid":"2470438","id":"PMC_2470438","title":"1H-NMR studies of receptor-selective substance P analogues reveal distinct predominant conformations in DMSO-d6.","date":"1989","source":"Biopolymers","url":"https://pubmed.ncbi.nlm.nih.gov/2470438","citation_count":34,"is_preprint":false},{"pmid":"30158126","id":"PMC_30158126","title":"The Atypical Chemokine Receptor Ackr2 Constrains NK Cell Migratory Activity and Promotes Metastasis.","date":"2018","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/30158126","citation_count":33,"is_preprint":false},{"pmid":"22504926","id":"PMC_22504926","title":"Control of murine Ly6C(high) monocyte traffic and immunosuppressive activities by atypical chemokine receptor D6.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22504926","citation_count":32,"is_preprint":false},{"pmid":"37056937","id":"PMC_37056937","title":"CXCL14 promotes metastasis of non-small cell lung cancer through ACKR2-depended signaling pathway.","date":"2023","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37056937","citation_count":31,"is_preprint":false},{"pmid":"11744379","id":"PMC_11744379","title":"The mouse enhancer element D6 directs Cre recombinase activity in the neocortex and the hippocampus.","date":"2002","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/11744379","citation_count":31,"is_preprint":false},{"pmid":"28123388","id":"PMC_28123388","title":"ACKR2: An Atypical Chemokine Receptor Regulating Lymphatic Biology.","date":"2017","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28123388","citation_count":30,"is_preprint":false},{"pmid":"22651933","id":"PMC_22651933","title":"The atypical chemokine receptor D6 controls macrophage efferocytosis and cytokine secretion during the resolution of inflammation.","date":"2012","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/22651933","citation_count":30,"is_preprint":false},{"pmid":"19642876","id":"PMC_19642876","title":"The chemokine scavenging receptor D6 limits acute toxic liver injury in vivo.","date":"2009","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19642876","citation_count":30,"is_preprint":false},{"pmid":"28674178","id":"PMC_28674178","title":"CCL5 Promotes Resolution-Phase Macrophage Reprogramming in Concert with the Atypical Chemokine Receptor D6 and Apoptotic Polymorphonuclear Cells.","date":"2017","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/28674178","citation_count":30,"is_preprint":false},{"pmid":"12960748","id":"PMC_12960748","title":"Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients.","date":"2003","source":"Psychiatric genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12960748","citation_count":30,"is_preprint":false},{"pmid":"18676013","id":"PMC_18676013","title":"Inflammatory reaction and implantation: the new entries PTX3 and D6.","date":"2008","source":"Placenta","url":"https://pubmed.ncbi.nlm.nih.gov/18676013","citation_count":29,"is_preprint":false},{"pmid":"22921835","id":"PMC_22921835","title":"D6: the 'crowd controller' at the immune gateway.","date":"2012","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22921835","citation_count":28,"is_preprint":false},{"pmid":"27568525","id":"PMC_27568525","title":"Spread of Psoriasiform Inflammation to Remote Tissues Is Restricted by the Atypical Chemokine Receptor ACKR2.","date":"2016","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/27568525","citation_count":27,"is_preprint":false},{"pmid":"31995405","id":"PMC_31995405","title":"ACKR2 contributes to pulmonary dysfunction by shaping CCL5:CCR5-dependent recruitment of lymphocytes during influenza A infection in mice.","date":"2020","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31995405","citation_count":26,"is_preprint":false},{"pmid":"23670187","id":"PMC_23670187","title":"Cell-autonomous regulation of neutrophil migration by the D6 chemokine decoy receptor.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/23670187","citation_count":26,"is_preprint":false},{"pmid":"35677043","id":"PMC_35677043","title":"The Role of Atypical Chemokine Receptor D6 (ACKR2) in Physiological and Pathological Conditions; Friend, Foe, or Both?","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35677043","citation_count":25,"is_preprint":false},{"pmid":"32030415","id":"PMC_32030415","title":"Abnormal uterine inflammation in obstetric syndromes: molecular insights into the role of chemokine decoy receptor D6 and inflammasome NLRP3.","date":"2020","source":"Molecular human reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/32030415","citation_count":24,"is_preprint":false},{"pmid":"18822328","id":"PMC_18822328","title":"Genetic variations of the chemokine scavenger receptor D6 are associated with liver inflammation in chronic hepatitis C.","date":"2008","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18822328","citation_count":24,"is_preprint":false},{"pmid":"29279330","id":"PMC_29279330","title":"MicroRNA-146 and cell trauma down-regulate expression of the psoriasis-associated atypical chemokine receptor ACKR2.","date":"2017","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29279330","citation_count":23,"is_preprint":false},{"pmid":"27888192","id":"PMC_27888192","title":"Atypical chemokine receptor ACKR2 controls branching morphogenesis in the developing mammary gland.","date":"2016","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/27888192","citation_count":22,"is_preprint":false},{"pmid":"26143454","id":"PMC_26143454","title":"Effects of Tarantula cubensis D6 on aflatoxin-induced injury in biochemical parameters in rats.","date":"2015","source":"Homeopathy : the journal of the Faculty of Homeopathy","url":"https://pubmed.ncbi.nlm.nih.gov/26143454","citation_count":22,"is_preprint":false},{"pmid":"17073737","id":"PMC_17073737","title":"Leucocyte expression of the chemokine scavenger D6.","date":"2006","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/17073737","citation_count":22,"is_preprint":false},{"pmid":"25297873","id":"PMC_25297873","title":"Atypical chemokine receptor ACKR2 mediates chemokine scavenging by primary human trophoblasts and can regulate fetal growth, placental structure, and neonatal mortality in mice.","date":"2014","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25297873","citation_count":21,"is_preprint":false},{"pmid":"35463452","id":"PMC_35463452","title":"Multi-Omics Analysis Reveals That SlERF.D6 Synergistically Regulates SGAs and Fruit Development.","date":"2022","source":"Frontiers in plant science","url":"https://pubmed.ncbi.nlm.nih.gov/35463452","citation_count":20,"is_preprint":false},{"pmid":"23642048","id":"PMC_23642048","title":"Molecular changes induced by the curcumin analogue D6 in human melanoma cells.","date":"2013","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23642048","citation_count":20,"is_preprint":false},{"pmid":"2808347","id":"PMC_2808347","title":"Selective oxidation of methionine beta(55)D6 at the alpha 1 beta 1 interface in hemoglobin completely destabilizes the T-state.","date":"1989","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2808347","citation_count":20,"is_preprint":false},{"pmid":"33409877","id":"PMC_33409877","title":"Histone Deacetylase Sirtuin 2 Enhances Viability of Trophoblasts Through p65-Mediated MicroRNA-146a/ACKR2 Axis.","date":"2021","source":"Reproductive sciences (Thousand Oaks, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/33409877","citation_count":19,"is_preprint":false},{"pmid":"24013383","id":"PMC_24013383","title":"Expression of the chemokine decoy receptor D6 is decreased in colon adenocarcinomas.","date":"2013","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/24013383","citation_count":19,"is_preprint":false},{"pmid":"31115765","id":"PMC_31115765","title":"Similarities and differences in d6 low-spin ruthenium, rhodium and iridium half-sandwich complexes: synthesis, structure, cytotoxicity and interaction with biological targets.","date":"2019","source":"Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31115765","citation_count":19,"is_preprint":false},{"pmid":"25348934","id":"PMC_25348934","title":"The atypical chemokine receptor ACKR2 suppresses Th17 responses to protein autoantigens.","date":"2014","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/25348934","citation_count":18,"is_preprint":false},{"pmid":"29589840","id":"PMC_29589840","title":"The Atypical Chemokine Receptor ACKR2 is Protective Against Sepsis.","date":"2018","source":"Shock (Augusta, Ga.)","url":"https://pubmed.ncbi.nlm.nih.gov/29589840","citation_count":18,"is_preprint":false},{"pmid":"20401387","id":"PMC_20401387","title":"Conformational ensembles of flexible beta-turn mimetics in DMSO-d6.","date":"2010","source":"Organic & biomolecular chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20401387","citation_count":18,"is_preprint":false},{"pmid":"23946783","id":"PMC_23946783","title":"Atypical chemokine receptor D6 inhibits human non-small cell lung cancer growth by sequestration of chemokines.","date":"2013","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/23946783","citation_count":17,"is_preprint":false},{"pmid":"11703181","id":"PMC_11703181","title":"Site-specific nickase from bacillus species strain d6.","date":"2001","source":"Biochemistry. Biokhimiia","url":"https://pubmed.ncbi.nlm.nih.gov/11703181","citation_count":17,"is_preprint":false},{"pmid":"2177083","id":"PMC_2177083","title":"Analysis of the fowlpox virus genome region corresponding to the vaccinia virus D6 to A1 region: location of, and variation in, non-essential genes in poxviruses.","date":"1990","source":"The Journal of general virology","url":"https://pubmed.ncbi.nlm.nih.gov/2177083","citation_count":17,"is_preprint":false},{"pmid":"28916283","id":"PMC_28916283","title":"Deuterated (d6)-dextromethorphan elicits antidepressant-like effects in mice.","date":"2017","source":"Pharmacology, biochemistry, and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/28916283","citation_count":15,"is_preprint":false},{"pmid":"24468675","id":"PMC_24468675","title":"A facile and versatile methodology for cysteine specific labeling of proteins with octahedral polypyridyl d⁶ metal complexes.","date":"2014","source":"Journal of inorganic biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24468675","citation_count":15,"is_preprint":false},{"pmid":"26798651","id":"PMC_26798651","title":"Renal Protection by Genetic Deletion of the Atypical Chemokine Receptor ACKR2 in Diabetic OVE Mice.","date":"2015","source":"Journal of diabetes research","url":"https://pubmed.ncbi.nlm.nih.gov/26798651","citation_count":14,"is_preprint":false},{"pmid":"21544515","id":"PMC_21544515","title":"Transgenic expression of murine chemokine decoy receptor D6 by islets reveals the role of inflammatory CC chemokines in the development of autoimmune diabetes in NOD mice.","date":"2011","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/21544515","citation_count":14,"is_preprint":false},{"pmid":"16989818","id":"PMC_16989818","title":"The effects of charge-neutralizing mutation D6.30N on the functions of CB1 and CB2 cannabinoid receptors.","date":"2006","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/16989818","citation_count":14,"is_preprint":false},{"pmid":"32230817","id":"PMC_32230817","title":"The Aza-Analogous Benzo[c]phenanthridine P8-D6 Acts as a Dual Topoisomerase I and II Poison, thus Exhibiting Potent Genotoxic Properties.","date":"2020","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/32230817","citation_count":14,"is_preprint":false},{"pmid":"28476575","id":"PMC_28476575","title":"Contribution of atypical chemokine receptor 2/ackr2 in bone remodeling.","date":"2017","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/28476575","citation_count":13,"is_preprint":false},{"pmid":"29176798","id":"PMC_29176798","title":"The scavenging chemokine receptor ACKR2 has a significant impact on acute mortality rate and early lesion development after traumatic brain injury.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/29176798","citation_count":13,"is_preprint":false},{"pmid":"34245621","id":"PMC_34245621","title":"Elucidating the structure and functions of Resolvin D6 isomers on nerve regeneration with a distinctive trigeminal transcriptome.","date":"2021","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/34245621","citation_count":13,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47653,"output_tokens":7926,"usd":0.130924,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17513,"output_tokens":7101,"usd":0.132545,"stage2_stop_reason":"end_turn"},"total_usd":0.263469,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"Human ACKR2 (D6) is a promiscuous beta-chemokine receptor that binds the majority of CC chemokines but not alpha-chemokines, C, or CXXXC chemokines; unlike conventional chemokine receptors, it does not flux calcium upon ligand binding, indicating it lacks canonical signaling capacity.\",\n      \"method\": \"Radioligand binding assays in transfected CHO cells; calcium flux assays in HEK293 cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct binding assays and calcium flux experiments replicated independently for murine and human D6 in the same year across two papers\",\n      \"pmids\": [\"9405404\", \"9139699\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Murine D6 binds multiple beta-chemokines with the order of affinity: murine MIP-1alpha > human/murine MIP-1beta > human RANTES ≈ JE > human MCP-3 > human MCP-1; alpha-chemokines did not compete; D6 does not function as an HIV-1 entry co-receptor on CD4+ cells.\",\n      \"method\": \"Competitive radioligand binding (125I-MIP-1alpha) in CHO transfectants; HIV infection assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — quantitative in vitro binding assays with multiple ligands, replicated across two independent 1997 papers\",\n      \"pmids\": [\"9139699\", \"9405404\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"ACKR2 (D6) is expressed by lymphatic endothelial cells of afferent lymphatics in human dermis, intestinal mucosa/submucosa, and lymph node sinuses, but not by blood vascular endothelium or peripheral blood cells, establishing its anatomical localization.\",\n      \"method\": \"Immunohistochemistry with monoclonal anti-D6 antibodies; in situ hybridization; co-staining with podoplanin lymphatic marker on serial sections\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal protein and mRNA detection with two orthogonal methods on multiple tissue types, replicated by subsequent studies\",\n      \"pmids\": [\"11238036\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ACKR2 (D6) engagement by inflammatory CC chemokines elicits no calcium response or chemotaxis but results in efficient agonist internalization and degradation; in lymphatic endothelium, D6 does not mediate transcytosis in either direction but solely internalizes and degrades chemokines.\",\n      \"method\": \"Calcium flux assays, chemotaxis assays, and chemokine internalization/degradation assays in D6 transfectants and primary lymphatic endothelial cells\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal functional assays in both transfected and primary cells; independently confirmed by subsequent studies\",\n      \"pmids\": [\"12594248\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"D6 constitutively traffics to and from the cell surface via recycling endosomes in a ligand-independent manner; chemokines internalized by D6 dissociate from the receptor upon vesicle acidification and are degraded, while the receptor recycles to the surface without cell surface downregulation—unlike conventional receptors such as CCR5.\",\n      \"method\": \"Live-cell fluorescence microscopy, subcellular fractionation, chemokine internalization and degradation kinetics assays compared between D6 and CCR5 transfectants\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct localization by imaging plus functional chemokine trafficking assays with mechanistic comparator (CCR5), replicated conceptually across multiple subsequent studies\",\n      \"pmids\": [\"15004236\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ACKR2 (D6) constitutive internalization is mediated by the clathrin-coated pit pathway and requires constitutive association with beta-arrestin; an acidic region in the cytoplasmic tail (but not putative phosphorylation sites) is critical for beta-arrestin interaction and subsequent internalization; D6 does not activate any G-protein-mediated signaling pathway regardless of beta-arrestin coupling status.\",\n      \"method\": \"Clathrin pathway inhibitor studies; co-immunoprecipitation of D6 with beta-arrestin; C-terminal deletion/mutagenesis of D6; G-protein signaling assays in transfected cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal methods including mutagenesis and Co-IP; mechanistic dissection of distinct receptor domains\",\n      \"pmids\": [\"15084596\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Purified D6 protein retains full functional activity (displaceable 125I-MIP-1beta binding); D6 is N-glycosylated at the N-terminus (dispensable for ligand binding and high expression), sulphated, and constitutively phosphorylated in a ligand-independent manner; >80% of total cellular D6 is associated with intracellular vesicular structures.\",\n      \"method\": \"Protein purification, radioligand binding (125I-MIP-1beta), MIP-1alpha affinity column, N-terminal glycosylation mutants, metabolic labelling for sulphation and phosphorylation, subcellular fractionation\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstituted purified receptor functional assays combined with mutagenesis and metabolic labelling in a single study\",\n      \"pmids\": [\"14723600\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"D6 efficiently binds and scavenges most inflammatory CCR1–CCR5 agonists but not homeostatic CCR6/CCR7 agonists; CCR4 agonists CCL17 and CCL22 are bound and scavenged by D6 but elicit no calcium flux or chemotaxis; CD26-processed truncated forms of CCL22 (lacking an intact N-terminus) are not recognized by D6.\",\n      \"method\": \"D6 transfectant binding assays, chemokine scavenging assays, calcium flux, chemotaxis assays, and testing of CD26-truncated CCL22 variants\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — systematic ligand panel with multiple functional readouts and N-terminal processing analysis in a single study\",\n      \"pmids\": [\"15067078\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"D6-deficient mice develop exacerbated and prolonged cutaneous inflammatory responses following phorbol ester application, with excess beta-chemokines at the site; wild-type mice resolve the response, demonstrating that D6 is required for post-inflammatory clearance of CC chemokines from cutaneous sites.\",\n      \"method\": \"D6-knockout mouse model with phorbol ester-induced skin inflammation; ELISA chemokine quantification; histopathological analysis\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function in vivo with chemokine measurement and histopathology; independently replicated in multiple subsequent studies using D6-/- mice\",\n      \"pmids\": [\"15750596\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"D6 can function as a coreceptor for primary dual-tropic HIV-1 and HIV-2 isolates on primary astrocytes; siRNA-mediated knockdown of D6 in primary astrocytes inhibited infection by D6-tropic isolates.\",\n      \"method\": \"HIV pseudovirus and primary isolate infection assays; siRNA knockdown of D6 in primary astrocytes; mRNA and immunoreactivity detection in macrophages and astrocytes\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — siRNA knockdown with defined functional readout in primary cells, single lab, single study\",\n      \"pmids\": [\"16014924\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"D6 is expressed on the apical surface of syncytiotrophoblast cells and on invading extravillous trophoblasts in placenta; D6-deficient pregnant mice exposed to LPS or antiphospholipid autoantibodies show higher CC chemokine levels and increased leukocyte infiltrate in placenta, causing increased fetal loss that is prevented by blocking inflammatory chemokines.\",\n      \"method\": \"Immunohistochemistry with anti-D6 antibodies in placenta; D6-/- mouse model with LPS and antiphospholipid antibody challenges; chemokine ELISA; antibody-mediated chemokine blockade rescue experiment\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with defined cellular mechanism and rescue experiment confirming chemokine-dependence, multiple orthogonal methods\",\n      \"pmids\": [\"17283337\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"D6 scavenging activity depends on Rab4- and Rab11-dependent constitutive recycling; under resting conditions, D6 cycles via a rapid wortmannin-sensitive pathway and a slower BFA-sensitive pathway. Chemokine engagement induces dose-dependent, BFA-sensitive, Rab11-dependent redistribution of D6 to the cell membrane, increasing chemokine degradation rate without transcriptional upregulation.\",\n      \"method\": \"Wortmannin and brefeldin A (BFA) pharmacological inhibition; dominant-negative Rab4 and Rab11 overexpression; flow cytometry of surface D6; chemokine degradation assays in transfected cells\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — multiple pharmacological and dominant-negative genetic tools with quantitative functional readouts in a single study\",\n      \"pmids\": [\"18480427\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"D6 expression in hematopoietic cells (B cells, dendritic cells, mast cells, megakaryocytes) is transcriptionally regulated by GATA1; D6 on human leukocytes mediates chemokine uptake as demonstrated by competition assays, whereas D6-null mouse cells fail to clear inflammatory chemokines.\",\n      \"method\": \"GATA1 knockdown/overexpression; promoter analysis; competition chemokine uptake assays in human leukocytes; comparison with D6-null mouse cells\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — GATA1 transcription factor regulation shown by functional promoter assays and leukocyte uptake experiments; single lab\",\n      \"pmids\": [\"18714007\", \"19039854\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The conserved 58-amino acid C-terminal tail of D6 contains a serine cluster that controls constitutive phosphorylation, intracellular trafficking itinerary, and high receptor stability, and drives beta-arrestin to membranes near the cell surface; however, the C-terminus is dispensable for initial chemokine internalization. Without the C-terminus, initial CCL3 binding inhibits subsequent chemokine uptake, indicating the C-terminus prevents ligand-induced inhibition of receptor recycling and is required for progressive scavenging.\",\n      \"method\": \"C-terminal deletion and serine cluster mutants of D6-GFP; beta-arrestin-GFP recruitment assays; CCL3 scavenging assays in HEK293 cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis with defined functional readouts (trafficking, scavenging) and GFP-tagged protein reporters in a single mechanistic study\",\n      \"pmids\": [\"18201974\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"D6-mediated chemokine degradation (but not binding) correlates with the receptor's adaptive surface upregulation; a proline residue at position 2 of D6-binding chemokines is dispensable for binding but is critical for D6 adaptive upregulation and efficient degradation, determining whether a bound chemokine is degraded or merely bound.\",\n      \"method\": \"D6 transfectant assays with panels of CC chemokines and their N-terminally truncated/processed isoforms; flow cytometry of surface D6; ELISA-based degradation assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — systematic structure-function analysis of chemokine N-termini with two orthogonal functional readouts; single lab\",\n      \"pmids\": [\"19632987\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"D6 expressed on lymphatic endothelial cells prevents inflammatory CC chemokine binding to lymphatic surfaces, thereby avoiding inappropriate perilymphatic accumulation of inflammatory leukocytes; this prevents lymphatic congestion and maintains selective CCR7 ligand presentation, ensuring proper dendritic cell and fluid migration from inflamed tissues to lymph nodes.\",\n      \"method\": \"D6-/- mouse model; intravital microscopy; flow cytometry of LEC-bound chemokines; antigen-presenting cell migration assays; lymph node fluid drainage measurements\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function mouse model with multiple orthogonal readouts; independently confirmed by McKimmie et al. 2013\",\n      \"pmids\": [\"21979941\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"D6 receptor activity (chemokine internalization) is a universal and unique feature of all known innate-like B-cell populations in mice; D6 on these cells internalizes chemokines but cannot induce Ca2+ fluxes or chemotaxis; additionally, D6 can suppress CXCR5 function in innate-like B cells.\",\n      \"method\": \"Flow cytometry-based chemokine uptake assay on primary B-cell subsets; Ca2+ flux assays; chemotaxis assays; analysis of D6-/- mice for B1 cell populations and anti-phosphorylcholine antibody levels\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — primary cell functional assays with loss-of-function confirmation; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"21450903\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Engagement of ACKR2 (D6) by ligands activates a beta-arrestin1-dependent, G-protein-independent signaling pathway resulting in phosphorylation of cofilin through Rac1-PAK1-LIMK1 cascade; this pathway is required for ligand-induced D6 surface upregulation and chemokine-scavenging activity.\",\n      \"method\": \"Phospho-cofilin immunoblotting; dominant-negative Rac1 and PAK1 inhibitors; beta-arrestin1 siRNA knockdown; D6 surface expression and chemokine scavenging assays\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — novel signaling pathway established by multiple genetic and pharmacological perturbations with two orthogonal functional readouts; mechanistically distinct from prior models\",\n      \"pmids\": [\"23633677\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"D6 on lymphatic endothelial cells (LECs) specifically regulates LEC discrimination between mature and immature dendritic cells; D6 overexpression reduces immature DC adhesion to LECs whereas D6 knockdown increases iDC adhesion and displacement of mature DCs. LEC D6 expression is upregulated by IL-6 and IFN-γ, and by Kaposi sarcoma-associated herpesvirus viral IL-6.\",\n      \"method\": \"D6 overexpression and knockdown in primary LEC cultures; DC adhesion assays; cytokine treatment; viral IL-6 overexpression in vitro and in vivo\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function experiments in primary cells with defined functional readout; single lab\",\n      \"pmids\": [\"23479571\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"D6 expressed on apoptotic neutrophils plays a chemokine scavenging-independent role in promoting macrophage-mediated resolution of inflammation; D6-expressing apoptotic PMN suppress macrophage cytokine secretion (immune silencing) and modulate macrophage adhesive responses upon engulfment, effects abolished with D6-deficient PMN cells.\",\n      \"method\": \"In vivo peritonitis model with D6-/- mice; ex vivo macrophage-PMN co-culture efferocytosis and cytokine secretion assays; flow cytometry\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function in vivo and ex vivo with defined mechanistic output; single lab\",\n      \"pmids\": [\"22651933\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ACKR2 scavenges the CCL2 chemokine to reciprocally regulate lymphatic vessel density: ACKR2-deficient mice display increased lymphatic vessel density that is developmentally established, associated with enhanced macrophage proximity to developing lymphatic vessels; CCR2-deficient mice show the reciprocal phenotype of reduced vessel density.\",\n      \"method\": \"ACKR2-/- and CCR2-/- mouse models; immunofluorescence for lymphatic vessel density and macrophage localization; embryonic skin analysis; fluid drainage measurement\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal genetic loss-of-function with two knockout strains showing opposing phenotypes; multiple tissue analyses and developmental time points\",\n      \"pmids\": [\"25271254\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Primary human trophoblasts express ACKR2 at far higher levels than conventional inflammatory CC chemokine receptors and use ACKR2 to rapidly internalize and efficiently scavenge extracellular chemokines; in DBA/1j mice, ACKR2 deficiency in fetal cells causes placental structural defects, increased stillbirth, and reduced fetal weight.\",\n      \"method\": \"RT-PCR and flow cytometry of ACKR2 in primary human trophoblasts; chemokine internalization/scavenging assays; ACKR2-/- and fetal-specific ACKR2 knockout mouse models; placental histology\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — human primary cell functional assays plus fetal-specific mouse KO experiments with multiple orthogonal endpoints\",\n      \"pmids\": [\"25297873\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ACKR2 controls inflammatory T-cell chemotaxis and positioning within skin, preventing epidermal T-cell influx associated with lesion development; localized inflammation and IFN-γ upregulate ACKR2 in remote tissues, protecting them from spread of psoriasiform inflammation.\",\n      \"method\": \"Imiquimod-induced psoriasiform model in ACKR2-/- mice; in vitro T-cell migration assays; IFN-γ treatment of primary human cells; clinical skin biopsy analysis\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function mouse model with defined cellular mechanism and in vitro confirmation; single lab\",\n      \"pmids\": [\"27568525\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"miR-146b and miR-10b directly bind the ACKR2 3'-UTR and reduce ACKR2 transcript and protein expression in keratinocytes and lymphatic endothelial cells, respectively; tensile cell stress leads to rapid ACKR2 downregulation concurrent with miR-146b upregulation, providing a mechanism for trauma-induced reduction of ACKR2 (Koebner phenomenon).\",\n      \"method\": \"Luciferase 3'-UTR reporter assays; in silico miRNA target prediction; RT-PCR and Western blot in primary human cells; cell stretch/mechanical stress experiments\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — direct 3'-UTR reporter assay plus mechanical stress experiment in primary cells; single lab\",\n      \"pmids\": [\"29279330\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ACKR2 is expressed in hematopoietic precursors and downregulated during myeloid differentiation; genetic deletion of ACKR2 increases expression of inflammatory chemokine receptors on neutrophils and promotes their release from bone marrow with enhanced anti-metastatic activity.\",\n      \"method\": \"ACKR2-/- mouse models; flow cytometry of bone marrow and circulating cells; chemokine receptor expression profiling; in vivo metastasis models (4T1 mammary and B16F10 melanoma)\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function in vivo with defined cellular mechanism; single lab, multiple endpoints\",\n      \"pmids\": [\"29445158\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Ackr2 deficiency leads to increased CCR2 expression specifically on KLRG1+ NK cells, resulting in increased recruitment of these cells to CCL2-expressing tumors and enhanced tumor killing; Ackr2 thus limits CCR2 expression on NK cells and restricts their tumoricidal activity.\",\n      \"method\": \"Ackr2-/- mouse models; cell line and spontaneous metastasis models; flow cytometry for NK cell subset markers and CCR2 expression; in vivo tumor killing assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function mouse model with defined NK cell-CCR2 mechanism; single lab\",\n      \"pmids\": [\"30158126\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ACKR2 mediates CXCL14-stimulated epithelial-to-mesenchymal transition, migration, and invasion in breast cancer cells; ACKR2 loss-of-function abolishes CXCL14-induced responses, and downregulation of ACKR2 or CXCL14-induced NOS1 attenuates these pro-EMT effects, identifying an autocrine fibroblast CXCL14/ACKR2 pathway.\",\n      \"method\": \"siRNA knockdown of ACKR2 in breast cancer cells; in vitro EMT, migration, invasion assays; in vivo xenograft and tail-vein metastasis models; NOS1 inhibition\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with defined signaling mechanism and in vivo confirmation; single lab\",\n      \"pmids\": [\"30850359\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CXCL10 (a CXC chemokine) is an agonist ligand for ACKR2, able to recruit beta-arrestin and be internalized and degraded by ACKR2, expanding the receptor's ligand range beyond CC chemokines; CD26/DPP4 N-terminal processing of CXCL10 drastically reduces its activity toward ACKR2, suggesting a different receptor binding pocket occupancy than CC chemokines.\",\n      \"method\": \"Beta-arrestin recruitment assays using NanoBiT and NanoBRET technologies; chemokine internalization and extracellular availability assays; DPP4-processed CXCL10 functional testing\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — highly sensitive functional assays with two orthogonal technologies; single lab; expands established paradigm\",\n      \"pmids\": [\"33801414\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Sirtuin 2 (SIRT2) promotes p65 deacetylation to suppress miR-146a expression, which in turn targets ACKR2; downregulation of miR-146a thus upregulates ACKR2 in trophoblasts, enhancing their proliferation, migration, and invasion; this SIRT2/p65/miR-146a/ACKR2 axis is disrupted in preeclampsia.\",\n      \"method\": \"ChIP assay; luciferase reporter assay confirming miR-146a targeting of ACKR2 3'-UTR; SIRT2 overexpression; miR-146a overexpression; HTR-8/SVneo trophoblast cell functional assays\",\n      \"journal\": \"Reproductive sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — ChIP and luciferase assays with mechanistic chain confirmed by gain/loss-of-function; single lab\",\n      \"pmids\": [\"33409877\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ACKR2 mediates CXCL14-induced lung cancer cell metastasis through activation of PLCβ3, PKCα, and c-Src signaling, subsequently upregulating NF-κB transcription activity leading to EMT and increased cell migration; ACKR2 knockdown abolishes CXCL14-induced cancer cell motility.\",\n      \"method\": \"ACKR2 knockdown studies; Western blot for PLCβ3/PKCα/c-Src/NF-κB pathway activation; luciferase NF-κB reporter assay; migration and wound healing assays; orthotopic mouse metastasis model\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with defined signaling cascade and in vivo confirmation; single lab\",\n      \"pmids\": [\"37056937\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ACKR2+ chemoradiotherapy-resistant tumor cells drive CD8+ T cell senescence by producing TGF-β in response to CC chemokines produced by activated myeloid and T cells; ACKR2 expression in tumor cells is upregulated by chemoradiotherapy and by CC chemokine ligation, creating a feed-forward loop that compromises antitumor immunity.\",\n      \"method\": \"Single-cell RNA sequencing of human cervical cancer tissues before/after CCRT; mechanistic validation of ACKR2-TGF-β-CD8+ T cell senescence axis in functional assays\",\n      \"journal\": \"Cell reports. Medicine\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — mechanistic claim derived primarily from single-cell transcriptomics with limited direct experimental validation described in abstract; single study\",\n      \"pmids\": [\"38723624\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ACKR2 (D6) is a heptahelical atypical chemokine receptor that constitutively cycles through Rab4/Rab11-dependent recycling endosomes to the plasma membrane, where it binds and internalizes most inflammatory CC chemokines (and CXCL10) via the clathrin pathway in a beta-arrestin-dependent manner; internalized chemokines dissociate from the receptor upon vesicle acidification and are degraded while the receptor recycles, maintaining surface expression; ligand engagement activates a beta-arrestin1/Rac1/PAK1/LIMK1/cofilin pathway that drives adaptive surface upregulation to increase scavenging capacity; the C-terminal serine cluster controls receptor stability, constitutive phosphorylation, and trafficking to prevent ligand-induced inhibition of recycling; expressed prominently on lymphatic endothelial cells, trophoblasts, and hematopoietic cells (regulated by GATA1 and miR-146b/miR-10b), ACKR2 scavenges inflammatory CC chemokines to suppress inflammation, regulate lymphatic vessel density and function, modulate neutrophil and NK cell trafficking, and protect against fetal loss and pathological inflammation in multiple tissues.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ACKR2 (D6) is an atypical, non-signaling chemokine scavenging receptor that suppresses inflammation by binding, internalizing, and degrading the majority of inflammatory CC chemokines (and CXCL10) without coupling to the canonical G-protein calcium/chemotaxis output of conventional chemokine receptors [#0, #3, #27]. Mechanistically, the receptor constitutively cycles between recycling endosomes and the plasma membrane in a ligand-independent, Rab4/Rab11-dependent manner; internalized chemokines dissociate upon endosomal acidification and are degraded while the receptor recycles back to the surface without downregulation, enabling sustained scavenging [#4, #11]. Internalization proceeds through the clathrin pathway and requires constitutive association with beta-arrestin via an acidic cytoplasmic-tail region, while the conserved C-terminal serine cluster controls constitutive phosphorylation, receptor stability, trafficking itinerary, and prevents ligand-induced inhibition of recycling to permit progressive scavenging [#5, #13]. Ligand engagement triggers a beta-arrestin1-dependent, G-protein-independent Rac1–PAK1–LIMK1–cofilin cascade that drives adaptive surface upregulation and increases scavenging capacity, with chemokine degradation (distinct from mere binding) determined by an N-terminal proline at ligand position 2 [#14, #17]. Expressed prominently on lymphatic endothelial cells, trophoblasts, and hematopoietic cells, ACKR2 limits perilymphatic accumulation of inflammatory leukocytes and preserves CCR7-dependent dendritic cell migration, reciprocally regulates lymphatic vessel density through CCL2 clearance, restricts neutrophil and NK-cell trafficking, and protects against inflammation-driven fetal loss [#10, #15, #20, #21, #24, #25]. In vivo loss of ACKR2 produces exacerbated, poorly resolving inflammatory responses with excess local CC chemokines [#8]. In tumor contexts, ACKR2 also transduces CXCL14-driven EMT and metastatic signaling [#26, #29].\"\n  ,\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Established that ACKR2 is a promiscuous CC chemokine binder that, unlike conventional chemokine receptors, fails to flux calcium, defining it as a non-signaling receptor and raising the question of its function.\",\n      \"evidence\": \"Radioligand binding and calcium flux assays in transfected CHO and HEK293 cells for human and murine D6\",\n      \"pmids\": [\"9405404\", \"9139699\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish the cellular fate of bound chemokines\", \"No in vivo function defined\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Localized ACKR2 to lymphatic endothelium of afferent lymphatics and lymph node sinuses, anchoring its function to a specific anatomical compartment rather than blood vasculature.\",\n      \"evidence\": \"Immunohistochemistry, in situ hybridization, and podoplanin co-staining across human tissues\",\n      \"pmids\": [\"11238036\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not test functional consequence of lymphatic expression\", \"Hematopoietic expression not yet defined\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Resolved the receptor's function by showing that ligand engagement leads to efficient internalization and degradation rather than transcytosis or chemotaxis, defining ACKR2 as a chemokine scavenger.\",\n      \"evidence\": \"Internalization/degradation assays in transfectants and primary lymphatic endothelial cells\",\n      \"pmids\": [\"12594248\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Trafficking machinery not yet identified\", \"Did not determine how the receptor avoids downregulation\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Defined the trafficking logic of scavenging: constitutive ligand-independent recycling with endosomal acidification driving chemokine release and degradation while the receptor returns to the surface.\",\n      \"evidence\": \"Live-cell imaging, subcellular fractionation, and degradation kinetics comparing D6 to CCR5\",\n      \"pmids\": [\"15004236\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific Rab GTPases not yet identified\", \"Endocytic adaptors not yet defined\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identified the internalization machinery and biochemical features, showing clathrin- and beta-arrestin-dependent uptake via an acidic tail region and confirming the absence of G-protein signaling.\",\n      \"evidence\": \"Clathrin inhibitors, beta-arrestin Co-IP, C-terminal mutagenesis, G-protein assays, and purified-receptor binding plus metabolic labelling\",\n      \"pmids\": [\"15084596\", \"14723600\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Role of C-terminal phosphorylation in trafficking unresolved\", \"Did not address adaptive surface regulation\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Defined the ligand spectrum, establishing that ACKR2 scavenges inflammatory but not homeostatic chemokines and that intact chemokine N-termini are required for recognition.\",\n      \"evidence\": \"Systematic chemokine binding/scavenging panel including CD26-truncated CCL22 in transfectants\",\n      \"pmids\": [\"15067078\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not distinguish binding from degradation determinants\", \"Did not extend to CXC chemokines\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Provided the first in vivo loss-of-function evidence that ACKR2 is required to resolve cutaneous inflammation by clearing CC chemokines.\",\n      \"evidence\": \"Phorbol ester skin inflammation in D6-knockout mice with chemokine ELISA and histopathology\",\n      \"pmids\": [\"15750596\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell-type-specific contributions not dissected\", \"Did not address other tissues\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Raised an alternative pathogen-related role by implicating D6 as an HIV coreceptor on primary astrocytes.\",\n      \"evidence\": \"HIV infection assays with siRNA knockdown in primary astrocytes\",\n      \"pmids\": [\"16014924\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab, single study\", \"Conflicts with earlier finding that D6 is not an HIV coreceptor on CD4+ cells\", \"Physiological relevance unclear\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Extended scavenging function to the placenta, showing ACKR2 protects against inflammation-driven fetal loss in a chemokine-dependent manner.\",\n      \"evidence\": \"Placental immunohistochemistry plus D6-/- LPS/antiphospholipid challenge with chemokine-blockade rescue\",\n      \"pmids\": [\"17283337\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Maternal versus fetal source of ACKR2 not resolved here\", \"Mechanism of trophoblast scavenging not detailed\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified the trafficking machinery and the adaptive scavenging mechanism: Rab4/Rab11-dependent recycling and ligand-induced membrane redistribution that boosts degradation without transcription.\",\n      \"evidence\": \"Wortmannin/BFA inhibition, dominant-negative Rab4/Rab11, flow cytometry, and degradation assays\",\n      \"pmids\": [\"18480427\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling driving redistribution not yet identified\", \"Link to C-terminal regulation unresolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Defined transcriptional control by GATA1 and confirmed functional scavenging on human leukocytes, broadening expression beyond endothelium to hematopoietic cells.\",\n      \"evidence\": \"GATA1 perturbation, promoter analysis, and leukocyte uptake assays versus D6-null cells\",\n      \"pmids\": [\"18714007\", \"19039854\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Direct GATA1 binding to endogenous locus not fully mapped\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Dissected the C-terminal serine cluster's role in phosphorylation, stability, trafficking, and prevention of ligand-induced inhibition of recycling required for progressive scavenging.\",\n      \"evidence\": \"C-terminal/serine-cluster mutants of D6-GFP with beta-arrestin recruitment and CCL3 scavenging assays\",\n      \"pmids\": [\"18201974\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the kinase phosphorylating the serine cluster unknown\", \"Did not connect to the downstream signaling cascade\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Separated binding from degradation, identifying a chemokine position-2 proline as the determinant of adaptive upregulation and efficient degradation.\",\n      \"evidence\": \"Chemokine N-terminal isoform panels with surface D6 flow cytometry and degradation ELISA\",\n      \"pmids\": [\"19632987\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Structural basis of proline recognition not determined\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Established the lymphatic physiological role: ACKR2 prevents perilymphatic inflammatory chemokine accumulation to preserve CCR7-dependent dendritic cell and fluid migration.\",\n      \"evidence\": \"D6-/- intravital microscopy, LEC chemokine flow cytometry, and APC migration/drainage assays\",\n      \"pmids\": [\"21979941\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address lymphatic developmental patterning\", \"Cell-intrinsic versus tissue effects not fully separated\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Showed ACKR2 scavenging is a universal feature of innate-like B cells and can suppress CXCR5 function, linking it to B-cell positioning.\",\n      \"evidence\": \"Chemokine uptake, Ca2+ flux, chemotaxis assays on primary B-cell subsets and D6-/- analysis\",\n      \"pmids\": [\"21450903\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Mechanism of CXCR5 suppression unresolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identified the signaling cascade behind adaptive scavenging: a beta-arrestin1/Rac1/PAK1/LIMK1/cofilin pathway driving surface upregulation, reconciling a non-G-protein receptor with active signaling output.\",\n      \"evidence\": \"Phospho-cofilin immunoblotting, dominant-negative Rac1/PAK1, beta-arrestin1 siRNA, and scavenging assays\",\n      \"pmids\": [\"23633677\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How ligand binding initiates the cascade not fully defined\", \"In vivo relevance of the cascade untested\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Connected lymphatic ACKR2 to immune surveillance by showing it controls LEC discrimination between mature and immature dendritic cells, with cytokine and viral IL-6 regulation.\",\n      \"evidence\": \"LEC overexpression/knockdown DC adhesion assays with IL-6/IFN-gamma and viral IL-6 treatment\",\n      \"pmids\": [\"23479571\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Molecular basis of DC discrimination unresolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Revealed a developmental role linking CCL2 scavenging to reciprocal control of lymphatic vessel density via macrophage proximity.\",\n      \"evidence\": \"Reciprocal ACKR2-/- and CCR2-/- mouse phenotyping with embryonic skin imaging and drainage measurement\",\n      \"pmids\": [\"25271254\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Macrophage signal driving lymphangiogenesis not fully defined\", \"Direct CCL2 gradients not measured in vivo\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrated that trophoblast-intrinsic ACKR2 mediates chemokine scavenging required for normal placental structure and fetal viability.\",\n      \"evidence\": \"Primary human trophoblast scavenging assays and fetal-specific ACKR2 knockout mouse models\",\n      \"pmids\": [\"25297873\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific pathogenic chemokines in placenta not fully resolved\", \"Mechanism of structural defect unclear\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Showed ACKR2 controls inflammatory T-cell positioning in skin and protects remote tissues from psoriasiform inflammation spread, induced by IFN-gamma.\",\n      \"evidence\": \"Imiquimod psoriasiform model in ACKR2-/- mice with T-cell migration assays and clinical biopsies\",\n      \"pmids\": [\"27568525\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Remote-tissue protection mechanism partial\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified post-transcriptional control of ACKR2 by miR-146b and miR-10b, including stress-induced downregulation, providing a mechanism for trauma-triggered loss of scavenging.\",\n      \"evidence\": \"3'-UTR luciferase reporters and cell-stretch experiments in primary keratinocytes and LECs\",\n      \"pmids\": [\"29279330\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"In vivo relevance of miRNA regulation untested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Linked ACKR2 to myeloid development and neutrophil release, showing its deletion enhances anti-metastatic neutrophil activity by raising inflammatory chemokine receptor expression.\",\n      \"evidence\": \"ACKR2-/- bone marrow profiling and 4T1/B16F10 metastasis models\",\n      \"pmids\": [\"29445158\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Cell-intrinsic versus niche effects not fully separated\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Showed ACKR2 limits CCR2 expression on KLRG1+ NK cells, restricting their CCL2-driven recruitment and tumoricidal activity.\",\n      \"evidence\": \"Ackr2-/- metastasis models with NK subset flow cytometry and in vivo killing assays\",\n      \"pmids\": [\"30158126\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Mechanism of CCR2 limitation on NK cells unresolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Reframed ACKR2 in cancer as a signaling receptor mediating CXCL14-induced EMT, migration, and invasion via NOS1 in breast cancer cells.\",\n      \"evidence\": \"ACKR2 siRNA knockdown with EMT/migration/invasion assays and xenograft/metastasis models\",\n      \"pmids\": [\"30850359\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Reconciliation with non-signaling scavenger model not addressed\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Expanded the ligand range by establishing CXCL10 as a CC-independent agonist that recruits beta-arrestin and is degraded, with distinct binding-pocket determinants.\",\n      \"evidence\": \"NanoBiT/NanoBRET beta-arrestin recruitment and internalization assays plus DPP4-processed CXCL10 testing\",\n      \"pmids\": [\"33801414\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Structural basis of CXC versus CC recognition not determined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined an upstream regulatory axis (SIRT2/p65/miR-146a) controlling trophoblast ACKR2 expression and linked its disruption to preeclampsia.\",\n      \"evidence\": \"ChIP, miR-146a 3'-UTR luciferase reporters, and SIRT2/miR-146a perturbation in HTR-8/SVneo trophoblasts\",\n      \"pmids\": [\"33409877\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"In vivo validation of the axis limited\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Extended the CXCL14/ACKR2 signaling axis to lung cancer, mapping a PLCβ3/PKCα/c-Src/NF-κB cascade driving EMT and metastasis.\",\n      \"evidence\": \"ACKR2 knockdown with pathway immunoblotting, NF-kB luciferase, migration assays, and orthotopic metastasis model\",\n      \"pmids\": [\"37056937\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Receptor coupling mechanism to PLCβ3 not defined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Proposed that ACKR2+ chemoradiotherapy-resistant tumor cells drive CD8+ T-cell senescence through CC-chemokine-induced TGF-beta in a feed-forward loop.\",\n      \"evidence\": \"Single-cell RNA sequencing of human cervical cancer with mechanistic validation of the ACKR2-TGF-beta-senescence axis\",\n      \"pmids\": [\"38723624\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Mechanistic claim derived primarily from transcriptomics with limited direct validation\", \"Single study\", \"Causality of ACKR2 in TGF-beta production not firmly established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the canonical non-signaling scavenging role of ACKR2 mechanistically reconciles with its reported active CXCL14-driven pro-tumor signaling remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model linking ligand-binding pocket to either scavenging or signaling output\", \"No unified framework explaining context-dependent signaling versus scavenging\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 3, 7]},\n      {\"term_id\": \"GO:0140313\", \"supporting_discovery_ids\": [3, 4, 11]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [5, 13, 17]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [4, 11]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [4, 6, 11]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [8, 15, 19]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [4, 5, 11]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [17]},\n      {\"term_id\": \"R-HSA-1500931\", \"supporting_discovery_ids\": [0, 3, 7]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"ARRB1\", \"RAC1\", \"PAK1\", \"LIMK1\", \"CFL1\", \"RAB11A\", \"RAB4A\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}